The new once-daily pill nearly doubled median survival in a major trial. Here is what the FDA approval means, who may qualify and what patients should know.
A new treatment option is now available for people with advanced pancreatic cancer.
The U.S. Food and Drug Administration approved Rasonque (daraxonrasib) on Aug. 26, 2026, as the first-in-class targeted therapy for metastatic pancreatic cancer. The once-daily pill is designed to block RAS proteins that help cancer cells grow.
For patients and families, the biggest question is simple: What does this approval actually mean?
Parriva first examined daraxonrasib earlier this year, when the drug was still moving through the FDA approval process. Now that approval has arrived, the question has changed from whether the treatment could become available to who can receive it and what the clinical results actually mean.
What is Rasonque?
Rasonque is a targeted cancer treatment called a RAS inhibitor.
RAS proteins help send signals that tell cells when to grow. When RAS signaling becomes abnormal, it can help cancer cells grow and spread.
Rasonque is designed to interfere with those signals. Unlike traditional chemotherapy, which can affect many rapidly dividing cells, targeted therapy is designed to interfere with a specific biological pathway involved in cancer.
The FDA-approved treatment is taken once a day by mouth.
Who can receive Rasonque?
The FDA approval is specifically for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment or who are not candidates for treatment with multiple chemotherapy drugs.
“Metastatic” means the cancer has spread from the pancreas to other parts of the body.
That means Rasonque is not a treatment for every person diagnosed with pancreatic cancer. A patient’s stage, previous treatments and overall health will help determine whether the drug is appropriate.
How much did Rasonque improve survival?
This is the most important finding behind the FDA approval.
In a randomized clinical trial involving 500 people with previously treated metastatic pancreatic adenocarcinoma, patients receiving Rasonque had a median overall survival of 13.2 months, compared with 6.7 months for patients receiving standard chemotherapy.
In other words, the median survival time was nearly twice as long in the Rasonque group.
But that does not mean Rasonque doubles every patient’s life expectancy or guarantees an additional six months of life. Clinical-trial results describe what happened to groups of patients, while individual results can be very different.
The trial also found median progression-free survival of 7.2 months with Rasonque versus 3.6 months with chemotherapy. The tumor response rate was 30% compared with 11%. FDA clinical-trial results
That finding is important because cancer survival is improving overall, but the benefits are not always shared equally. Parriva previously examined that broader issue in its look at cancer survival and the uneven risks facing Latino communities.
Is Rasonque a cure?
No.
The FDA approval is for metastatic pancreatic cancer, a serious and difficult-to-treat disease. The clinical trial showed that Rasonque improved survival and delayed disease progression compared with the chemotherapy used in the study.
It does not mean the cancer has been cured.
For a patient or family member, the important next step is to ask an oncologist whether Rasonque fits the patient’s diagnosis and previous treatment history.
What are the side effects?
The FDA says common side effects include:
- rash
- diarrhea
- inflammation of the mouth, known as stomatitis
- nausea
- fatigue
- vomiting
- abdominal pain
- swelling
- decreased appetite
- hemorrhage
The FDA also warns about potentially serious complications, including gastrointestinal perforation and lung inflammation. FDA safety information for Rasonque
Patients should talk with their cancer care team about new or worsening symptoms rather than stopping treatment on their own.
Is Rasonque available now?
Yes. FDA approval means Rasonque is now available by prescription for its approved use rather than being limited to clinical trials or special early-access programs.
The manufacturer says the medication is distributed through select oncology-focused specialty pharmacies.
That distinction matters for families. FDA approval makes the treatment available, but obtaining it can still involve a patient’s oncologist, insurance coverage and a specialty pharmacy.
What does this mean for Latino families?
The most important takeaway is not that Rasonque is a miracle drug.
It is that a new treatment option is now available for some people with metastatic pancreatic cancer after earlier treatment or for those who cannot receive multi-drug chemotherapy.
For Latino families, understanding the difference between FDA approval, eligibility and actual access is especially important. A treatment can be approved without being appropriate for every patient, and access can still depend on the healthcare system, insurance and the patient’s medical circumstances.
That is why the most useful question for a family facing advanced pancreatic cancer may be:
Could Rasonque be appropriate for this patient, and what are the potential benefits and risks compared with the other available treatments?
The FDA approval marks an important advance in pancreatic cancer treatment. But for patients and families, the real measure of that advance will be whether the right people can understand it, access it and use it safely.
For now, Rasonque gives some patients with advanced pancreatic cancer another treatment option and potentially more time.
